BioMarin Announces Record Revenues in First Quarter 2022 : v

BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11% Year-ov...

Related Keywords

Australia , Japan , United States , Slovenia , Italy , Czech Republic , Saudi Arabia , United Arab Emirates , Canada , American , Debra Charlesworth , Biomarin Aldurazyme , Valoctocogene Roxaparvovec , Traci Mccarty , Jean Jacques Bienaim , American Society Of Gene Cell Therapy , Biomarin Pharmaceutical Inc , Nasdaq , Replay International Number , Prnewswire Biomarin Pharmaceutical Inc , Biomarin Genzyme , Committee For Medicinal Products Human Use , Drug Administration , European Commission , World Federation Of Hemophilia , Exchange Commission , Development Expense , International Number , European Medicines Agency , Development Portfolio , World Congress , Total Revenues Grew , Voxzogo Net Product Revenues Increased , Remaining Guidance , Severe Hemophilia , Under Review , Medicinal Products , Human Use , Opinion Anticipated Mid Year , Biologics License Application , Analysis Complete , Vector Integration , Previously Announced Adverse , Months Ended March , Product Revenues Marketed , Net Product Revenues Marketed , Marin Pharmaceutical , Marin Announces Record Revenues , First Quarter , Chief Executive Officer , Total Revenues , Middle East , Rare Pediatric Disease Priority Review Voucher , Regulatory Portfolio , Marketing Authorization Application , American Society , Cell Therapy , World Federation , Hereditary Angioedema , Orphan Disease Designation , Duchenne Muscular Dystrophy , Year Financial Guidance , Administrative Expense , All Financial Guidance , Canada Dial In Number , Dial In Number , International Dial In Number , Biomarin Pharmaceutical , Net Product Revenues , Annual Report , Nonqualified Deferred Compensation Plan , Consolidated Financial Statements , Asset Amortization , Contingent Consideration , Intangible Asset , From Income Taxes , Year Ending , Guidance Year Ending December , Based Compensation ,